三阴性乳腺癌:组织病理学特征、基因组学与治疗
三阴性乳腺癌占乳腺癌的8%-13%,年轻女性比例更高,非西班牙裔黑人女性受影响更大,诊断后5年内复发风险最高。影像上常表现为良性形态,钼靶早期检出受限,超声优于钼靶但可因良性表现误诊,乳腺MRI是最敏感的检出方法;MRI是评估新辅助化疗反应的首选方法。局限期、区域性和远处转移患者的5年生存率分别为91.3%、65.8%和12.0%,免疫治疗的早期成功为个体化治疗带来希望,影像和肿瘤生物标志物未来可能在预测治疗反应和生存中起关键作用。
要点
- 三阴性乳腺癌比其他亚型更常表现为良性形态影像特征,超声可因良性表现导致误诊。
- 乳腺MRI是三阴性乳腺癌检出最敏感的检查方法,也是评估新辅助化疗反应的首选方法。
- 诊断时局限期、区域性和远处转移患者的5年生存率分别为91.3%、65.8%和12.0%。
核心结论
- 三阴性乳腺癌是异质性、侵袭性强的肿瘤,影像常表现良性形态,MRI是最敏感的检出方法并用于评估新辅助化疗反应,免疫治疗的早期成功为个体化治疗带来希望,影像和肿瘤生物标志物未来可能有助于预测治疗反应和生存。
研究设计与样本
- 本文为综述,未报告系统检索范围与纳入文献数量。
关键影像表现/征象
- 三阴性乳腺癌比其他乳腺癌亚型更常表现出良性形态的影像特征。
- 钼靶对三阴性乳腺癌早期检出可能不理想,原因包括肿瘤生长快、年轻女性乳腺密度增加以及缺乏典型恶性影像特征。
- 超声对三阴性乳腺癌的检出优于钼靶,但良性表现可导致误诊。
- 乳腺MRI是三阴性乳腺癌检出最敏感的检查方法。
- MRI是评估三阴性乳腺癌新辅助化疗反应的首选方法。
临床应用与阅片要点
- 大多数三阴性乳腺癌采用新辅助化疗,随后手术和放疗。
- MRI是评估三阴性乳腺癌新辅助化疗反应的首选方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive group of tumors that are defined by the absence of estrogen and progesterone receptors and lack of ERBB2 (formerly HER2 or HER2/neu) overexpression. TNBC accounts for 8%-13% of breast cancers. In addition, it accounts for a higher proportion of breast cancers in younger women compared with those in older women, and it disproportionately affects non-Hispanic Black women. TNBC has high metastatic potential, and the risk of recurrence is highest during the 5 years after it is diagnosed. TNBC exhibits benign morphologic imaging features more frequently than do other breast cancer subtypes. Mammography can be suboptimal for early detection of TNBC owing to factors that include the fast growth of this cancer, increased mammographic density in young women, and lack of the typical features of malignancy at imaging. US is superior to mammography for TNBC detection, but benign-appearing features can lead to misdiagnosis. Breast MRI is the most sensitive modality for TNBC detection. Most cases of TNBC are treated with neoadjuvant chemotherapy, followed by surgery and radiation. MRI is the modality of choice for evaluating the response to neoadjuvant chemotherapy. Survival rates for individuals with TNBC are lower than those for persons with hormone receptor-positive and human epidermal growth factor receptor 2-positive cancers. The 5-year survival rates for patients with localized, regional, and distant disease at diagnosis are 91.3%, 65.8%, and 12.0%, respectively. The early success of immunotherapy has raised hope regarding the development of personalized strategies to treat TNBC. Imaging and tumor biomarkers are likely to play a crucial role in the prediction of TNBC treatment response and TNBC patient survival in the future. ©RSNA, 2023 Quiz questions for this article are available in the supplemental material.
引用
- Adrada BE, Moseley TW, Kapoor MM, et al. Triple-Negative Breast Cancer: Histopathologic Features, Genomics, and Treatment. Radiographics. 2023. PMID: 37792593. doi:10.1148/rg.230034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。